GNRH ANTAGONISTS IN ASSISTED REPRODUCTION (A REVIEW)

Close metadata

Recommended articles:

Assisted reproductive technologies and the risk of placenta accreta. Russian Journal of Human Reproduction. 2024;(3):43-49

IVF outcomes with various degrees of pathozoospermia. Russian Journal of Human Reproduction. 2024;(3):115-120

Calcium-phosphorus metabolism and assisted reproductive technologies: intersection points. Russian Journal of Human Reproduction. 2024;(4):19-28

The dilemma of management of patients with endometrioma and infertility. Russian Journal of Human Reproduction. 2024;(4):29-37

The place of GnRH antagonists in modern ART programs: the possibilities of using of new drug of ganirelix. Russian Journal of Human Reproduction. 2024;(4):38-50

An integrated approach to endometrial examination in case of repeated failures in ART cycles: a pilot study. Russian Journal of Human Reproduction. 2024;(4):51-58

Regulatory control of gestagens use in Russia in the era of individualized luteal phase support for assisted reproduction cycles. Russian Journal of Human Reproduction. 2024;(4):59-70

The influence of embryo culture technologies using traditional and TLT incubators on reproductive outcomes in women with different prognoses for the success of in vitro fertilization. Russian Journal of Human Reproduction. 2024;(4):71-77

Correlation dependence of tissue inhibitor of metalloproteinase-1 levels and follicular fluid morphology in patients with combined (uterine myoma and endometriosis) infertility in the ART-programs. Russian Bulletin of Obstetrician-Gynecologist. 2024;(4):21-28

Comparative analysis of oocyte quality in patients with tubal-peritoneal genesis of infertility in assisted reproductive technology programs. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):41-49

The review focuses on the current use of GnRH antagonists in assisted reproduction. Existing premature LH surge prevention protocols with GnRH antagonists and their role in routine clinical practice are discussed. In addition, the review highlights modern strategies to improve the pregnancy rate in assisted reproduction.

Keywords:

GnRH antagonists

premature LH surge

assisted reproduction

Authors:

Barkalina N.V.

FGU "Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii im. akad. V.I. Kulakova" Minzdravsotsrazvitiia Rossii, Moskva

Mishieva N.G.

FGU "Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii im. akad. V.I. Kulakova" Minzdravsotsrazvitiia Rossii, Moskva

Abubakirov A.N.

FGU "Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii im. akad. V.I. Kulakova" Minzdravsotsrazvitiia Rossii, Moskva

List of references:

Klingmuller D., Schepke M., Enzweiler C., Bidlingmaier F. Hormonal responses to the new potent GnRH antagonist Cetrorelix. Acta Endocrinol (Copenh) 1993; 128: 15-18.
Tarlatzis B.C., Fauser B.C., Kolibianakis E.M. et al. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 2006; 12: 4: 333-340.
Reissmann T., Schally A.V., Bouchard P. et al. The LHRH antagonist cetrorelix: a review. Hum Reprod Update 2000; 6: 4: 322-331.
Kolibianakis E.M., Tarlatzis B.C., Devroey P. GnRH antagonists in IVF. Reprod Biomed Online 2005; 10: 705-712.
Al-Inany H.G., Abou-Setta A.M., Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online 2007; 14: 5: 640-649.
Johnston-MacAnanny E.B., DiLuigi A.J., Engmann L.L. et al. Selection of first in vitro fertilization cycle stimulation protocol for good prognosis patients: gonadotropin releasing hormone antagonist versus agonist protocols. J Reprod Med 2011; 56: 1-2: 12-16.
Nazarenko T.A. Stimulyatsiya funktsii yaichnikov. M: MEDpress-inform 2008.
Olivennes F., Belaisch-Allart J., Emperaire J.C. et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000; 73: 314-320.
Wilcox J., Potter D., Moore M. et al. Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies. Fertil Steril 2005; 84: 108-117.
Al-Inany H.G., Aboulghar M., Mansour R., Serour G.I. Optimizing GnRH antagonist administration: metaanalysis of fixed vs flexible protocol. Reprod Biomed Online 2005; 10: 567.
Kolibianakis E.M., Venetis C.A., Kalogeropoulou L. et al. Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial. Fertil Steril 2011; 95: 2: 558-562.
Elnashar A.M. Progesterone rise on the day of HCG administration (premature luteinization) in IVF: an overdue update. J Ass Reprod Genet 2010; 27: 4: 149-155.
Hofmann G.E., Bentzien F., Bergh P.A. et al. Premature luteinization in controlled ovarian hyperstimulation has no adverse effect on oocyte and embryo quality. Fertil Steril 1993; 60: 675-679.
Silverberg K.M., Martin M., Olive D.L. et al. Elevated serum progesterone levels on the day of human chorionic gonadotropin administration in in vitro fertilization cycles do not adversely affect embryo quality. Fertil Steril 1994; 61: 508-513.
Fanchin R., Ziegler D., Taieb J. et al. Premature elevation of plasma progesterone alters pregnancy rates of in vitro fertilization and embryo transfer. Fertil Steril 1993; 59: 1090-1094.
Harada T., Yoshida S., Katagiri C. et al. Reduced implantation rate associated with a subtle rise in serum progesterone concentration during the follicular phase of cycles stimulated with a combination of a gonadotrophin-releasing hormone agonist and gonadotrophin. Hum Reprod 1995; 10: 1060-1064.
Bosch E., Valencia I., Escudero E. et al. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril 2003; 80: 1444-1449.
Labarta E., Martínez-Conejero J.A., Alamá P. et al. Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod 2011.
Li R., Qiao J., Wang L. et al. MicroRNA array and microarray evaluation of endometrial receptivity in patients with high serum progesterone levels on the day of hCG administration. Reprod Biol Endocrinol 2011; 6: 9: 29.
Lainas T.G., Petsas G.K., Zorzovilis I.Z. et al. Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development. Hum Reprod 2007; 22: 6: 1540-1546.
Brzyski R.G., Muasher S.J., Droesch K. et al. Follicular atresia associated with concurrent initiation of gonadotropin-releasing hormone agonist and follicle-stimulating hormone for oocyte recruitment. Fertil Steril 1988; 50: 6: 917-921.
Gelety T.J., Pearlstone A.C., Surrey E.S. Short-term endocrine response to gonadotropin-releasing hormone agonist initiated in the early follicular, midluteal, or late luteal phase in normally cycling women. Fertil Steril 1995; 64: 6: 1074-1080.
San Roman G.A., Surrey E.S., Judd H.L. et al. A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization. Fertil Steril 1992; 58: 4: 744-749.
Griesinger G., Kolibianakis E.M., Venetis C. et al. Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis. Fertil Steril 2010; 94: 6: 2382-2384.
Younis J.S., Soltsman S., Izhaki I. et al. Early and short follicular gonadotropin-releasing hormone antagonist supplementation improves the meiotic status and competence of retrieved oocytes in in vitro fertilization-embryo transfer cycles. Fertil Steril 2010; 94: 4: 1350-1355.
Tang Y., Gong F., Lin G. et al. Early follicular progesterone concentrations and in vitro fertilization pregnancy outcomes. Fertil Steril 2007; 87: 4: 991-994.
Blockeel C., Baumgarten M., De Vos M. et al. Administration of GnRH antagonists in case of elevated progesterone at initiation of the cycle: a prospective cohort study. Curr Pharm Biotechnol 2011; 12: 3: 423-428.
Blockeel C., Riva A., De Vos M. et al. Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm injection treatment cycle: impact on ovarian stimulation. A pilot study. Fertil Steril 2011; 95: 5: 1714-1719.
Al-Inany H.G., Youssef M.A., Aboulghar M. et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011; 11: 5: CD001750.
Al-Inany H.G., Youssef M.A., Aboulghar M. et al. GnRH antagonists are safer than agonists: an update of a Cochrane review. Hum Reprod Update 2011; 17: 4: 435

Close metadata